HDEF - ETF AI Analysis

Top Page

Xtrackers MSCI EAFE High Dividend Yield Equity ETF (HDEF)

Rating:68Neutral

Price Target:―

The Xtrackers MSCI EAFE High Dividend Yield Equity ETF (HDEF) benefits from strong contributions by holdings like Novartis AG, which showcases robust profitability, a stable balance sheet, and growth in key products, and Roche Holding AG, known for its strong cash flow management and strategic pharmaceutical initiatives. However, weaker-performing holdings like British American Tobacco, which faces earnings volatility and lacks strong momentum, may have slightly weighed on the overall rating. A key risk factor for this ETF is its concentration in a few high-weighted holdings, which could amplify the impact of any underperformance in those stocks.

Positive Factors

Strong Top Holdings

Several of the largest positions, such as Roche Holding AG and Iberdrola, have delivered strong year-to-date performance, supporting the ETF's overall returns.

Low Expense Ratio

The ETF charges a very low expense ratio, making it a cost-effective choice for investors.

Geographic Diversification

The fund is spread across multiple countries, including the UK, Switzerland, and Japan, reducing reliance on any single economy.

Negative Factors

Sector Concentration in Financials

The ETF has a high allocation to the financial sector, which could make it vulnerable to downturns in that industry.

Underperforming Holding

TotalEnergies SE, one of the top 10 holdings, has shown negative year-to-date performance, which may drag on the fund's overall returns.

Limited U.S. Exposure

With only 1.12% allocated to U.S. companies, the fund may miss out on growth opportunities in the world's largest economy.

HDEF vs. SPDR S&P 500 ETF (SPY)

AUM2.18B

RegionDeveloped Markets

Expense Ratio0.09%

Beta0.41

IssuerXtrackers

Inception DateAug 12, 2015

Dividend Yield3.8%

Asset ClassEquity

Index TrackedMSCI EAFE High Dividend Yield

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume167,598

30 Day Avg. Volume128,352

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

32.04

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering115

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

HDEF Summary

The Xtrackers MSCI EAFE High Dividend Yield Equity ETF (HDEF) is an investment fund that focuses on companies outside the U.S. and Canada, specifically in developed markets like Europe, Japan, and Australia. It follows the MSCI EAFE High Dividend Yield Index, which includes established companies known for paying high dividends. Some of its top holdings include well-known names like Novartis and Shell. This ETF is ideal for investors looking to diversify globally while earning steady income through dividends. However, since it focuses on international markets, its performance can be affected by global economic conditions and currency fluctuations.

How much will it cost me?The expense ratio for HDEF is 0.09%, which means you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because HDEF is passively managed, tracking an index rather than relying on active stock selection.

What would affect this ETF?HDEF could benefit from stable dividend payouts and growth in developed markets outside North America, especially if sectors like financials and healthcare, which have significant weight in the ETF, perform well. However, challenges such as rising interest rates, economic slowdowns in Europe or Asia, or regulatory changes affecting top holdings like Novartis or Shell could negatively impact returns. Diversification across sectors and regions provides some resilience, but global economic conditions remain a key factor to watch.

HDEF Top 10 Holdings

The HDEF ETF leans heavily on financials, healthcare, and consumer defensive sectors, with a clear focus on high-dividend-paying companies across developed markets outside North America. Roche and Novartis are steady contributors, benefiting from robust pipelines and stable profitability, while British American Tobacco has been rising on strong cash flow and dividend appeal. On the flip side, Unilever and Zurich Insurance are lagging, weighed down by mixed technical trends and valuation concerns. Overall, the fund’s sector concentration in financials and healthcare provides stability, but some holdings are struggling to keep pace.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ROG	Roche Holding AG	5.21%	$114.09M	CHF250.59B	35.86%	73 Outperform
NOVN	Novartis AG	4.88%	$106.76M	CHF202.12B	14.17%	80 Outperform
NESN	Nestlé SA	4.80%	$105.10M	CHF199.66B	12.93%	71 Outperform
SHEL	Shell (UK)	4.79%	$104.82M	£159.60B	9.10%	74 Outperform
ALV	Allianz	4.40%	$96.24M	€140.80B	24.58%	67 Neutral
ULVR	Unilever	3.92%	$85.77M	£110.00B	-4.50%	77 Outperform
IBE	Iberdrola	3.51%	$76.79M	€119.44B	33.31%	67 Neutral
TTE	TotalEnergies SE	3.47%	$75.91M	€121.92B	-0.09%	78 Outperform
BATS	British American Tobacco	3.38%	$73.94M	£95.55B	49.15%	70 Neutral
SAN	Sanofi	2.94%	$64.46M	€105.04B	0.93%	77 Outperform

HDEF Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

29.78

Positive

100DMA

29.53

Positive

200DMA

28.28

Positive

Market Momentum

MACD

0.18

Negative

RSI

60.21

Neutral

STOCH

91.19

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HDEF, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.10, equal to the 50-day MA of 29.78, and equal to the 200-day MA of 28.28, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 60.21 is Neutral, neither overbought nor oversold. The STOCH value of 91.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HDEF.

HDEF Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
HDEF	―	―	$2.18B	0.09%	―
FDVV	―	―	$7.63B	0.15%	―
IDV	―	―	$6.32B	0.50%	―
DIVI	―	―	$1.95B	0.09%	―
DTH	―	―	$502.21M	0.58%	―
EFAS	―	―	$34.47M	0.56%	―

Performance Comparison

HDEF

Xtrackers MSCI EAFE High Dividend Yield Equity ETF

30.53

6.49

27.00%

FDVV

Fidelity High Dividend ETF

―

IDV

iShares International Select Dividend ETF

―

DIVI

Franklin LibertyQ International Equity Hedged ETF

―

DTH

WisdomTree International High Dividend Fund

―

EFAS

Global X MSCI SuperDividend EAFE ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents